{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = ''N''-[(2''R'')-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide
| image = Mibampator skeletal.svg
| width = 

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 375345-95-2
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 9889366
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 8065037
| UNII = A9V5BW73UU
| KEGG = D09931
| ChEBI = 
| ChEMBL = 1277001
| synonyms = LY-451395

<!--Chemical data-->
| C=21 | H=30 | N=2 | O=4 | S=2
| molecular_weight = 438.601 g/mol
| SMILES = C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C
| StdInChI_Ref = 
| StdInChI = 1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = ULRDYYKSPCRXAJ-KRWDZBQOSA-N
}}

'''Mibampator''' (developmental code name '''LY-451395''') is a [[positive allosteric modulator]] (PAM) of the [[AMPA receptor]] (AMPAR), an [[ionotropic glutamate receptor]], which was under development by [[Eli Lilly]] for the treatment of [[agitation (dementia)|agitation]]/[[aggression]] in [[Alzheimer's disease]] but was never marketed.<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800024387</ref><ref name="pmid20347881">{{cite journal | vauthors = Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, Castner SA | title = Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction | journal = Behav. Brain Res. | volume = 212 | issue = 1 | pages = 41–8 | year = 2010 | pmid = 20347881 | doi = 10.1016/j.bbr.2010.03.039 | url = }}</ref> It reached [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s prior to the discontinuation of its development.<ref name="AdisInsight" />

Mibampator belongs to the [[biarylpropylsulfonamide]] group of AMPAR PAMs, which also includes [[LY-404187]], [[LY-503430]], and [[PF-04958242]] among others.<ref name="pmid22886028">{{cite journal | vauthors = Froestl W, Muhs A, Pfeifer A | title = Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors | journal = J. Alzheimers Dis. | volume = 32 | issue = 4 | pages = 793–887 | year = 2012 | pmid = 22886028 | doi = 10.3233/JAD-2012-121186 | url = }}</ref> It is a "high-impact" AMPAR potentiator, unlike "low-impact" AMPAR potentiators from other classes like [[CX-516]] and its [[congener (chemistry)|congener]] [[farampator]] (CX-691, ORG-24448), and is able to elicit comparatively more robust increases in AMPAR signaling.<ref name="pmid20347881" /> In animals, high-impact AMPAR potentiators enhance [[cognition]] and [[memory]] at low doses, but produce [[motor coordination]] [[motor disorder|disruption]]s, [[convulsion]]s, and [[neurotoxicity]] at higher doses.<ref name="pmid28242871">{{cite journal | vauthors = Ranganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, Gupta S, Cahill J, Sherif MA, Mancuso J, Zumpano L, D'Souza DC | title = Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242 | journal = Mol. Psychiatry | volume = | issue = | pages = | year = 2017 | pmid = 28242871 | doi = 10.1038/mp.2017.6 | url = }}</ref>

Mibampator failed to produce cognitive improvement in patients with Alzheimer's disease, though it did show improvements in neuropsychiatric measures.<ref name="pmid18291371">{{cite journal | vauthors = Zarate CA, Manji HK | title = The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases | journal = Exp. Neurol. | volume = 211 | issue = 1 | pages = 7–10 | year = 2008 | pmid = 18291371 | pmc = 2441819 | doi = 10.1016/j.expneurol.2008.01.011 | url = }}</ref> A caveat of the study was that the maximally tolerated dosage of the drug could not be used due to [[toxicity]], and dosages in the same range in rodents notably failed to improve memory-related behavior.<ref name="pmid19772371">{{cite journal | vauthors = Buccafusco JJ | title = Emerging cognitive enhancing drugs | journal = Expert Opin Emerg Drugs | volume = 14 | issue = 4 | pages = 577–89 | year = 2009 | pmid = 19772371 | doi = 10.1517/14728210903257796 | url = }}</ref>

==See also==
* [[AMPA receptor positive allosteric modulator]]

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800024387 Mibampator - AdisInsight]


{{Nootropics}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:AMPA receptor positive allosteric modulators]]
[[Category:Nootropics]]
[[Category:Sulfonamides]]


{{Nervous-system-drug-stub}}